The combined evaluation of CNVs and fragmentation features in cfDNA was demonstrated to enhance the sensitivity of tumor-agnostic ctDNA quantification [23] and may improve response evaluation in NSCLC patients receiving PD-(L)1 blockade. The gene discussed is CD274; the disease is neoplasm.